Syringic acid, resveratrol and gallic acid compounds lipid metabolizing enzymes regulatory activity in isoproterenol-induced cardiac necrosis in rats

Abstract

Objective: The present investigation aimed to analyze the in vivo study in support with in silico molecular docking mechanism of natural phenolic compounds Syringic acid (SA), Resveratrol (RV), Gallic acid (GA) and combination (COMB) with SA + RV against Isoproterenol (ISO) in myocardial necrotic rats. Methods: The compounds were tested for in vivo and in silico lipid metabolism enzymes HMG-CoA reductase and lipoprotein lipase (LPL) regulatory activities. Rats were orally pretreated with 50 mg/ kg of each compounds SA, RV, GA and COMB (SA 25 mg/ kg + RV 25 mg/ kg) for 30 days. GA has taken as positive control. After the treatment period, ISO (50 mg/ kg) in sub-cutaneous route was administered to the rats for two consecutive days. Then the rats sacrificed and the cardiac tissues were used for enzyme inhibitory analysis. Results: SA, RV, GA and COMB exhibited HMG-CoA reductase enzyme inhibitory activity. Also, the compounds augmented the LPL enzyme activity in the rats administered with ISO. Furthermore, in silico molecular docking reports also supported to the activity of SA, RV, GA and COMB compounds towards the enzymes HMG-CoA reductase and LPL. Conclusion: This report for the first time indicates the potential of phenolic compounds SA, RV, GA and COMB as excellent natural compounds in the therapeutic treatment of lipid metabolism disorders.

Keywords

• Syringic acid
• Resveratrol
• Gallic acid
• Isoproterenol
• HMG-CoA reductase
• Lipoprotein lipase